单核苷酸多态性基因分型市场－全球产业规模、份额、趋势、机会及预测（按技术、应用、地区和竞争格局划分，2021-2031年）

全球单核苷酸多态性 (SNP) 基因分型市场预计将从 2025 年的 131.8 亿美元成长到 2031 年的 340.7 亿美元，复合年增长率达到 17.15%。

单核苷酸多态性（SNP）基因型鉴定是一种专门的分析方法，用于测量DNA序列特定位置的遗传变异，从而揭示与疾病和生理特征相关的标记。该市场的主要驱动力是全球向精准医疗的转型以及药物基因组学在临床实践中的应用，这需要精准的基因分析来实现个人化治疗。根据个人化医疗联盟（Personalized Medicine Coalition）预测，2024年将有18种新的个人化药物核准，占新核准治疗性分子实体总数的38%。这表明基因分型技术在患者分层和现代药物研发中扮演着至关重要的角色。

儘管成长指标积极，但该产业在敏感生物数据的管理方面仍面临许多挑战。其中一个关键挑战是基因资料隐私和安全监管环境的严格性，这可能会阻碍市场发展。遵守不断变化的国际资料保护标准的高成本和复杂的操作流程可能会成为小规模诊断检查室的进入门槛，并限制此类服务的广泛应用。

市场驱动因素

对基因组研究和生物银行投资的不断增长是单核苷酸多态性（SNP）基因型鉴定市场的主要驱动力，为大规模人群研究提供了必要的资金。各国政府和私人机构正向生物样本库投入大量资金，以建立强大的基因资料库，这对于检测疾病标记和开发精准医疗至关重要。这些资金的涌入直接促进了基因型鉴定晶片和定序平台的购置，而这些设备是分析数百万个生物样本所必需的。例如，2024年7月，英国政府宣布英国生物样本库（UK Biobank）已获得1,600万英镑的资金，用于升级其云端基础设施，以确保海量基因组资料集的安全储存和分析。同时，Illumina公司在2024年2月报告称，2023财年的全年收入将达到45亿美元，反映出全球对高通量基因分析工具的强劲需求。

此外，SNP基因分型在农业生物技术领域的广泛应用正将市场拓展至人类医学之外。农业科学家和育种家正积极利用基因分型进行标记辅助选择，以提高作物产量、增强抗病能力并改良牲畜性状，从而应对全球粮食安全挑战。这一趋势得到了公共部门的大力支持，这些资金旨在透过基因组技术的进步实现农业现代化。根据美国农业部（USDA）国家食品与农业研究所2023年12月发布的2024财年通知，将提供约3亿美元用于植物健康和动物育种遗传学等研究重点领域，以促进在标准农业实践中采用基于SNP的筛检。

市场挑战

全球单核苷酸多态性（SNP）基因型鉴定市场成长的主要障碍在于严格的基因资料隐私和安全法规结构。由于基因型鉴定分析的是高度敏感的DNA序列，用于检测生理特征和疾病标记物，因此该行业必须遵守复杂的国际资料保护条例网络，例如美国的HIPAA和欧洲的GDPR。这些法规对病患知情同意管理、资料加密和跨境资讯交流都制定了严格的标准。维持合规的高成本和营运复杂性构成了巨大的进入门槛，尤其对于缺乏大型製药公司资金支持的研究机构和小规模诊断检查室，这有效地限制了创新和市场竞争。

这种监管压力迫使企业将大量资源投入法律和合规基础建设，而非研发，直接阻碍了市场扩张。各行各业都面临着遵守这些规定的挑战。国际隐私专业人员协会 (IAPP) 的报告显示，仅有 20% 的隐私专业人员对其所在机构在 2024 年继续遵守不断变化的隐私法律的能力充满信心。这种不确定性阻碍了对新型基因分型倡议的投资，并减缓了精准医疗的发展，因为企业出于声誉受损和麵临严厉法律处罚的风险，对扩大业务规模仍然保持谨慎。

市场趋势

市场正迅速转向次世代定序(NGS) 技术，取代传统的晶片技术，实现对新突变和已知突变的同步检测。这项转变提供了复杂性状分析和精准医疗所需的精细基因组解析度。高精度定序平台的广泛应用推动了这一趋势，使研究人员能够对以往难以用传统技术分析的基因组区域进行精确的基因分型。近期硬体出货量凸显了这项技术发展。根据 Pacific Biosciences 截至 2025 年 2 月的财年财务报告，该公司在 2024 年第四季出货了 23 套 Revio定序系统，显示市场对高通量基因组基础设施的需求强劲。

同时，液态生物检体在非侵入性SNP检测领域的应用正在变革临床诊断。这项技术透过分析血液样本中的游离DNA，无需进行侵入性组织切片检查即可检测疾病相关突变，从而实现对癌症等疾病的持续监测。这项优势正推动高灵敏度基因分型方法在常规患者照护中的广泛应用。这种日益增强的整合也体现在服务量上。根据Natera公司截至2025年2月的财年财务报告，该公司在2024年第四季处理了约792,800份检测，凸显了非侵入性基因筛检应用领域的市场显着扩张。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球单核苷酸多态性基因分型市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术分类（TaqMan SNP基因型鉴定、Massarray SNP基因型鉴定、SNP GeneChip晶片、其他）
  • 按应用领域（动物遗传学、植物改良、诊断研究、药物和药物基因组学、农业生物技术等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美单核苷酸多态性基因分型市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲单核苷酸多态性基因分型市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区单核苷酸多态性基因分型市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲单核苷酸多态性基因分型市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲单核苷酸多态性基因分型市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球单核苷酸多态性基因分型市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• Douglas Scientific LLC
• Illumina Inc.
• Life Technologies Corp.
• Luminex Corp
• Promega Corporation
• Thermo Fischer Scientific Inc.
• Fluidigm Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Single Nucleotide Polymorphism Genotyping Market is projected to expand from USD 13.18 Billion in 2025 to USD 34.07 Billion by 2031, achieving a CAGR of 17.15%. Single Nucleotide Polymorphism genotyping is a specialized analytical method used to measure genetic variations at specific positions within DNA sequences to uncover markers associated with diseases or physiological traits. This market is primarily driven by the worldwide transition toward precision medicine and the integration of pharmacogenomics into clinical care, which requires precise genetic profiling for customized treatments. According to the Personalized Medicine Coalition, 18 new personalized medicines were FDA-approved in 2024, accounting for 38 percent of all newly authorized therapeutic molecular entities, highlighting the critical reliance on genotyping technologies for patient stratification and modern drug development.

Despite these positive growth indicators, the industry confronts significant obstacles regarding the management of sensitive biological data. A primary challenge that threatens to slow market progression is the rigorous regulatory environment governing genetic data privacy and security. The high costs and operational intricacies involved in adhering to shifting international data protection standards can erect entry barriers for smaller diagnostic laboratories and restrict the broader uptake of these services.

Market Driver

Rising investments in genomic research and biobanking serve as a major driver for the Single Nucleotide Polymorphism genotyping market, supplying essential capital for extensive population studies. Governments and private organizations are allocating significant funds to biobanks to establish robust genetic databases, which are crucial for detecting disease markers and creating precision therapies. This financial influx directly facilitates the acquisition of genotyping arrays and sequencing platforms needed to analyze millions of biological samples. For instance, the UK Government announced in July 2024 that the UK Biobank secured £16 million to modernize its cloud infrastructure, ensuring the secure storage and analysis of its massive genomic dataset, while Illumina reported full-year 2023 revenue of $4.50 billion in February 2024, reflecting strong global demand for high-throughput genetic analysis tools.

Additionally, the growing application of SNP genotyping in agricultural biotechnology is broadening the market's reach beyond human healthcare. Agricultural scientists and breeders are increasingly employing genotyping for marker-assisted selection to boost crop yields, enhance disease resistance, and refine livestock traits, thereby tackling global food security issues. This shift is bolstered by substantial public sector funding designed to modernize agriculture through genomic advancements. According to the USDA National Institute of Food and Agriculture's December 2023 notification for the 2024 cycle, approximately $300 million was made available to fund research priorities such as plant health and animal breeding genetics, incentivizing the adoption of SNP-based screening in standard agricultural practices.

Market Challenge

A significant obstacle restricting the growth of the Global Single Nucleotide Polymorphism (SNP) Genotyping Market is the strict regulatory framework regarding genetic data privacy and security. Because SNP genotyping entails analyzing highly sensitive DNA sequences to detect physiological traits and disease markers, the industry must comply with a complicated network of international data protection regulations, such as HIPAA in the United States and the GDPR in Europe. These laws enforce rigorous standards for patient consent management, data encryption, and cross-border information exchanges. The associated high costs and operational complexity of maintaining compliance establish substantial barriers to entry, especially for research institutions and smaller diagnostic laboratories without the financial backing of large pharmaceutical companies, effectively limiting innovation and market competition.

This regulatory pressure directly impedes market expansion by compelling organizations to allocate significant resources toward legal and compliance infrastructures instead of research and development. The challenge of adhering to these requirements is felt throughout the sector; according to the International Association of Privacy Professionals, only 20 percent of privacy experts expressed full confidence in their organization's ability to remain compliant with evolving privacy laws in 2024. This uncertainty deters investment in new genotyping initiatives and retards the advancement of precision medicine, as companies remain cautious about scaling operations given the risks of reputational damage and severe legal penalties.

Market Trends

The market is increasingly shifting toward Next-Generation Sequencing (NGS) technologies, which are replacing traditional arrays by allowing for the simultaneous detection of both novel and known variants. This transition offers the detailed genomic resolution necessary for complex trait analysis and advanced precision medicine. The growing adoption of high-fidelity sequencing platforms supports this movement, enabling researchers to accurately genotype challenging genomic regions that earlier technologies failed to resolve. Recent hardware distributions highlight this technological evolution; according to Pacific Biosciences' February 2025 financial report, the company shipped 23 Revio sequencing systems during the fourth quarter of 2024, signaling strong demand for high-throughput genomic infrastructure.

Concurrently, the application of liquid biopsy for non-invasive SNP detection is transforming clinical diagnostics. By examining cell-free DNA from blood samples, this method enables the detection of disease-linked mutations without the need for invasive tissue biopsies, allowing for the ongoing monitoring of conditions like cancer. This capability has driven the widespread adoption of highly sensitive genotyping assays in routine patient care. The extent of this integration is reflected in service volumes; according to Natera's February 2025 financial results, the company processed approximately 792,800 tests in the fourth quarter of 2024, emphasizing the significant market expansion in non-invasive genetic screening applications.

Key Market Players

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• Douglas Scientific LLC
• Illumina Inc.
• Life Technologies Corp.
• Luminex Corp
• Promega Corporation
• Thermo Fischer Scientific Inc.
• Fluidigm Corporation

Report Scope

In this report, the Global Single Nucleotide Polymorphism Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Single Nucleotide Polymorphism Genotyping Market, By Technology

• TaqMan SNP Genotyping
• Massarray SNP Genotyping
• SNP GeneChip Arrays
• Others

Single Nucleotide Polymorphism Genotyping Market, By Application

• Animal Genetics
• Plant Improvement
• Diagnostic Research
• Pharmaceuticals and Pharmacogenomics
• Agricultural Biotechnology
• Others

Single Nucleotide Polymorphism Genotyping Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Single Nucleotide Polymorphism Genotyping Market.

Available Customizations:

Global Single Nucleotide Polymorphism Genotyping Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Single Nucleotide Polymorphism Genotyping Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (TaqMan SNP Genotyping, Massarray SNP Genotyping, SNP GeneChip Arrays, Others)
  • 5.2.2. By Application (Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Single Nucleotide Polymorphism Genotyping Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Single Nucleotide Polymorphism Genotyping Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Single Nucleotide Polymorphism Genotyping Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Single Nucleotide Polymorphism Genotyping Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application

7. Europe Single Nucleotide Polymorphism Genotyping Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
  • 7.3.2. France Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Single Nucleotide Polymorphism Genotyping Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application

8. Asia Pacific Single Nucleotide Polymorphism Genotyping Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Single Nucleotide Polymorphism Genotyping Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
  • 8.3.2. India Single Nucleotide Polymorphism Genotyping Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Single Nucleotide Polymorphism Genotyping Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Single Nucleotide Polymorphism Genotyping Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Single Nucleotide Polymorphism Genotyping Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application

9. Middle East & Africa Single Nucleotide Polymorphism Genotyping Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Single Nucleotide Polymorphism Genotyping Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Single Nucleotide Polymorphism Genotyping Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Single Nucleotide Polymorphism Genotyping Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application

10. South America Single Nucleotide Polymorphism Genotyping Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Single Nucleotide Polymorphism Genotyping Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Single Nucleotide Polymorphism Genotyping Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Single Nucleotide Polymorphism Genotyping Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Single Nucleotide Polymorphism Genotyping Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bio-Rad Laboratories Inc.
• 15.3. Danaher Corporation
• 15.4. Douglas Scientific LLC
• 15.5. Illumina Inc.
• 15.6. Life Technologies Corp.
• 15.7. Luminex Corp
• 15.8. Promega Corporation
• 15.9. Thermo Fischer Scientific Inc.
• 15.10. Fluidigm Corporation

16. Strategic Recommendations

17. About Us & Disclaimer